Inside information: Orion provides outlook for 2026 and estimates that the annual Nubeqa® net sales recorded by Orion has potential to exceed EUR 1 billion in the future

Orion Corporation has made a significant announcement regarding its outlook for 2026, emphasizing the promising potential of its leading product, Nubeqa®. The company estimates that annual net sales from Nubeqa®, which includes tablet sales to Bayer and associated royalties, could exceed EUR 1 billion in the future. This estimation reflects the product's financial importance as it has already become Orion's largest product.

In its outlook for the year 2026, Orion projects net sales between EUR 1,900 million to EUR 2,100 million, with an operating profit estimated between EUR 550 million to EUR 750 million. The primary driver behind this growth is anticipated to be Nubeqa®, with its net sales expected to continue their upward trajectory in the coming years. This projection, however, is contingent upon variable conditions such as the regulatory landscape, market dynamics, and the specific indications for which Nubeqa® is utilized.

Notably, Orion's 2026 outlook does not incorporate any substantial milestone payments, indicating that the figures presented focus solely on existing product performance. Further details regarding the foundation of this outlook will be elucidated in the Financial Statement Release scheduled for February 12, 2026.

Orion Corporation, a reputable name in the Nordic pharmaceutical industry, has been dedicated to enhancing well-being for over a century. The company specializes in human and veterinary medicines, with key therapeutic areas including oncology and pain management. With approximately 3,700 employees worldwide, Orion stands ready to leverage its extensive portfolio of pharmaceuticals and consumer health products to meet future challenges and opportunities.

Orion Corporation’s recent announcement regarding the Nubeqa® product marks a significant turning point for the company, suggesting that its net sales could exceed EUR 1 billion in the near future. This development is paramount, as Nubeqa® has become the company’s largest product, leading to a projected net sales range of EUR 1.9 billion to EUR 2.1 billion and an operating profit of EUR 550 million to EUR 750 million for 2026.

The strategic partnership with Bayer plays a critical role in Nubeqa®’s growth trajectory. Given that the sales figures comprise both tablet sales to Bayer and royalty payments, investors should monitor Bayer's market performance and regulatory changes closely. Nubeqa®'s increasing significance posits Orion as a leader in oncology, a market that is poised for substantial growth due to rising global cancer incidences and a continuous need for innovative therapies.

While optimism is warranted, it is crucial to acknowledge the uncertainties mentioned in the outlook report, such as regulatory shifts and market dynamics that could potentially impact sales. As such, maintaining a diversified portfolio remains essential for investors looking to mitigate risk while benefiting from Orion's growth.

Looking ahead, the financial community should scrutinize the February 12, 2026 Financial Statement Release for deeper insights into the outlook’s assumptions and projections. This will provide a clearer picture of how Yubeqa® and other segments within Orion are set to perform against a backdrop of external challenges.

In conclusion, while Orion Corporation exhibits promising growth potential through Nubeqa®, investors should adopt a measured approach, acknowledging both the exciting opportunities and the inherent market risks.